RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology prize lecture

European Journal of Endocrinology

Volumn 155, Issue 5, 2006, Pages 645-653

  Santoro, Massimo ^a   Melillo, Rosa Marina ^a   Fusco, Alfredo ^a,b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN PATCHED; PROTEIN RET;

CANCER GENETICS; CELL TRANSFORMATION; GENE EXPRESSION; GENE REARRANGEMENT; GENETIC ASSOCIATION; HUMAN; KARYOTYPE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; THYROID CELL; THYROID PAPILLARY CARCINOMA;

ANIMALS; CARCINOMA, PAPILLARY; CHROMOSOMES, HUMAN, PAIR 10; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REARRANGEMENT; HUMANS; MAP KINASE SIGNALING SYSTEM; ONCOGENE PROTEINS, FUSION; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-RET; THYROID NEOPLASMS; TRANS-ACTIVATION (GENETICS);

EID: 33845255290     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.1.02289     Document Type: Review

References (91)

1. Takahashi M, Ritz J & Cooper GM. Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell 1985 42 581-588.
2. Airaksinen MS & Saarma M. The GDNF family: signalling, biological functions and therapeutic value. Nature Reviews Neuroscience 2002 3 383-394.
3. Marx SJ. Molecular genetics of multiple endocrine neoplasia types 1 and 2. Nature Reviews. Cancer 2005 5 367-375.
4. DeLellis RA & William ED. Thyroid and parathyroid tumors. In World Health Organization Classification of Tumours. Pathology and Genetics. Tumours of Endocrine organs, pp 51-56. Ed. RA DeLellis, RV Lloyd, PU Heitz & C Eng, Geneva: WHO Press, 2003.
5. Fusco A, Grieco M, Santoro M, Berlingieri MT, Pilotti S, Pierotti MA, Della Porta G & Vecchio G. A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases. Nature 1987 328 170-172.
6. Grieco M, Santoro M, Berlingieri MT, Melillo RM, Donghi R, Bongarzone I, Pierotti MA, Della Porta G, Fusco A & Vecchio G. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 1990 60 557-563.
7. Pierotti MA & Greco A. Oncogenic rearrangements of the NTRK1/NGF receptor. Cancer Letters 2006 232 90-98.
8. Tallini G & Asa SL. RET oncogene activation in papillary thyroid carcinoma. Advances in Anatomic Pathology 2001 8 345-354.
9. Nikiforov YE. RET/PTC rearrangement in thyroid tumors. Endocrine Pathology 2002 13 3-16.
10. Kondo T, Ezzat S & Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nature Reviews Cancer 2006 6 292-306.
11. Santoro M & Carlomagno F. Drug insight: small-molecule inhibitors of protein kinases in the treatment of thyroid cancer. Nature Clinical Practice. Endocrinology and Metabolism 2006 2 42-52.
12. Zhu Z, Ciampi R, Nikiforova MN, Gandhi M & Nikiforov YE. Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity. Journal of Clinical Endocrinology and Metabolism 2006 91 3603-3610.
13. Rhoden KJ, Unger K, Salvatore G, Yilmaz Y, Vovk V, Chiappetta G, Qumsiyeh MB, Rothstein JL, Fusco A, Santoro M, Zitzelsberger H & Tallini G. RET/papillary thyroid cancer rearrangement in non-neoplastic thyrocytes: follicular cells of Hashimoto's thyroiditis share low-level recombination events with a subset of papillary carcinoma. Journal of Clinical Endocrinology and Metabolism 2006 91 2414-2423.
14. Sugg SL, Ezzat S, Rosen IB, Freeman JL & Asa SL. Distinct multiple RET/ PTC gene rearrangements in multifocal papillary thyroid neoplasia. Journal of Clinical Endocrinology and Metabolism 1998 83 4116-4122.
15. Adeniran AJ, Zhu Z, Gandhi M, Steward DL, Fidler JP, Giordano TJ, Biddinger PW & Nikiforov YE. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. American Journal of Surgical Pathology 2006 30 216-222.
16. Fusco A, Chiappetta G, Hui P, Garcia-Rostan G, Golden L, Kinder BK, Dillon DA, Giuliano A, Cirafici AM, Santoro M, Rosai J & Tallini G. Assessment of RET/PTC oncogene activation and clonality in thyroid nodules with incomplete morphological evidence of papillary carcinoma: a search for the early precursors of papillary cancer. American Journal of Pathology 2002 60 2157-2167.
17. Cetta F, Chiappetta G, Melillo RM, Petracci M, Montalto G, Santoro M & Fusco A. The RET/PTC1 oncogene is activated in familial adenomatous polyposis-associated thyroid papillary carcinomas. Journal of Clinical Endocrinology and Metabolism 1998 83 1003-1006.
18. Cheung CC, Ezzat S, Ramyar L, Freeman JL, & Asa SL. Molecular basis of Hurthle cell papillary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 2000 85 878-882.
19. Chiappetta G, Toti P, Cetta F, Giuliano A, Pentimalli F, Amendola I, Lazzi S, Monaco M, Mazzuchelli L, Tosi P, Santoro M & Fusco A. The RET/ PTC oncogene is frequently activated in oncocytic thyroid tumors (Hurthle cell adenomas and carcinomas), but not in oncocytic hyperplastic lesions. Journal of Clinical Endocrinology and Metabolism 2002 87 364-369.
20. Cheung CC, Boerner SL, MacMillan CM, Ramyar L & Asa SL. Hyalinizing trabecular tumor of the thyroid: a variant of papillary carcinoma proved by molecular genetics. American Journal of Surgical Pathology 2000 24 1622-1626.
21. Papotti M, Volante M, Giuliano A, Fassina A, Fusco A, Bussolati G, Santoro M & Chiappetta G. RET/PTC activation in hyalinizing trabecular tumors of the thyroid. American Journal of Surgical Pathology 2000 24 1615-1621.
22. Nikiforov YE, Rowland JM, Bove KE, Monforte-Munoz H & Fagin JA. Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Research 1997 57 1690-1694.
23. Nikiforov YE. Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas. Endocrine Pathology 2004 15 319-327.
24. Bongarzone I, Vigneri P, Mariani L, Collini P, Pilotti S & Pierotti MA. RET/NTRK1 rearrangements in thyroid gland tumors of the papillary carcinoma family: correlation with clinicopathological features. Clinical Cancer Research 1998 4 223-228.
25. Jhiang SM, Caruso DR, Gilmore E, Ishizaka Y, Tahira T, Nagao M, Chiu IM & Mazzaferri EL. Detection of the PTC/retTPC oncogenc in human thyroid cancers. Oncogene 1992 7 1331-1337.
26. Soares P, Fonseca E, Wynford-Thomas D & Sobrinho-Simoes M. Sporadic ret-rearranged papillary carcinoma of the thyroid: a subset of slow growing, less aggressive thyroid neoplasms? Journal of Pathology 1998 185 71-78.
27. Tallini G, Santoro M, Helie M, Carlomagno F, Salvatore G, Chiappetta G, Carcangiu ML & Fusco A. RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. Clinical Cancer Research 1998 4 287-294.
28. Santoro M, Papotti M, Chiappetta G, Garcia-Rostan G, Volante M. Johnson C, Camp RL, Pentimalli F, Monaco C, Herrero A, Carcangiu ML, Fusco A & Tallini G. RET activation and clinicopathologic features in poorly differentiated thyroid tumors. Journal of Clinical Endocrinology and Metabolism 2002 87 370-379.
29. La Perle KM, Jhiang SM & Capen CC. Loss of p53 promotes anaplasia and local invasion in ret/PTC1-induced thyroid carcinomas. American Journal of Pathology 2000 157 671-677.
30. Ito T, Seyama T, Iwamoto KS, Hayashi T, Mizuno T, Tsuyama N, Dohi K, Nakamura N & Akiyama M. In vitro irradiation is able to cause RET oncogene rearrangement. Cancer Research 1993 53 2940-2943.
31. Mizuno T, Kyoizumi S, Suzuki T, Iwamoto KS & Seyama T. Continued expression of a tissue specific activated oncogene in the early steps of radiation-induced human thyroid carcinogenesis. Oncogene 1997 15 1455-1460.
32. Mizuno T, Iwamoto KS, Kyoizumi S, Nagamura H, Shinohara T, Koyama K, Seyama T & Hamatani K. Preferential induction of RET/PTC1 rearrangement by X-ray irradiation. Oncogene 2000 19 438-443.
33. Bounacer A, Wicker R, Caillou B, Cailleux AF, Sarasin A, Schlumberger M & Suarez HG. High prevalence of activating ret proto-oncogene rearrangements, in thyroid tumors from patients who had received external radiation. Oncogene 1997 15 1263-1273.
34. Collins BJ, Chiappetta G, Schneider AB, Santoro M, Pentimalli F, Fogelfeld L, Gierlowski T, Shore-Freedman E, Jaffe G & Fusco A. RET expression in papillary thyroid cancer from patients irradiated in childhood for benign conditions. Journal of Clinical Endocrinology and Metabolism 2002 87 3941-3946.
35. Alipov G, Ito M, Prouglo, Y, Takamura N & Yamashita S. Ret protooncogene rearrangement in thyroid cancer around Semipalatinsk nuclear testing site. Lancet 1999 354 1528-1529.
36. Williams D. Cancer after nuclear fallout: lessons from the Chernobyl accident. Nature Reviews Cancer 2002 2 543-549.
37. Fugazzola L, Pilotti S, Pinchera A, Vorontsova TV, Mondellini P Bongarzone I, Greco A, Astakhova L, Butti MG, Demidchik EP & Pierotti M. Oncogenic rearrangements of the RET proto-oncogene in papillary thyroid carcinomas from children exposed to the Chernobyl nuclear accident. Cancer Research 1995 55 5617-5620.
38. Rabes HM, Demidchik EP, Sidorow JD, Lengfelder E, Beimfohr C, Hoelzel D & Klugbauer S. Pattern of radiation-induced RET and NTRK1 rearrangements in 191 post-chernobyl papillary thyroid carcinomas: biological, phenotypic, and clinical implications. Clinical Cancer Research 2000 6 1093-1103.
39. Thomas GA, Bunnell H, Cook HA, Williams ED, Nerovnya A, Cherstvoy ED, Tronko ND, Bogdanova TI, Chiappetta G, Viglietto G, Pentimalli F, Salvatore G, Fusco A, Santoro M & Vecchio G. High prevalence of RET/ PTC rearrangements in Ukrainian and Belarussian post-Chernobyl thyroid papillary carcinomas: a strong correlation between RET/PTC3 and the solid-follicular variant. Journal of Clinical Endocrinology and Metabolism 1999 84 4232-4238.
40. Saad AG, Kumar S, Ron E, Lubin JH, Stanek J, Bove KE & Nikiforov YE. Proliferative activity of human thyroid cells in various age groups and its correlation with the risk of thyroid cancer after radiation exposure. Journal of Clinical Endocrinology and Metabolism 2006 91 2672-2677.
41. Bongarzone I, Fugazzola L, Vigneri P, Mariani L, Mondellini P, Pacini F, Basolo F, Pinchera A, Pilotti S & Pierotti MA. Age-related activation of the tyrosine kinase receptor protooncogenes RET and NTRK1 in papillary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 1996 81 2006-2009.
42. Powell N, Jeremiah S, Morishita M, Dudley E, Bethel J, Bogdanova T, Tronko M & Thomas G. Frequency of BRAF T1796A mutation in papillary thyroid carcinoma relates to age of patient at diagnosis and not to radiation exposure. Journal of Pathology 2005 205 558-564.
43. Ciampi R, Knauf JA, Kerler R, Gandhi M, Zhu Z. Nikiforova MN, Rabes HM, Fagin JA & Nikiforov YE. Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. Journal of Clinical Investigation 2005 115 94-101.
44. Lima J, Trovisco V, Soares P, Maximo V, Magalhaes J, Salvatore G, Santoro M, Bogdanova T, Tronko M, Abrosimov A, Jeremiah S, Thomas G, Williams D & Sobrinho-Simoes M. BRAF mutations are not a major event in post-Chernobyl childhood thyroid carcinomas. Journal of Clinical Endocrinology and Metabolism 2004 89 4267-4271.
45. Nikiforova MN, Stringer JR, Blough R, Medvedovic M, Fagin JA & Nikiforov YE. Proximity of chromosomal loci that participate in radiation-induced rearrangements in human cells. Science 2000 290 138-141.
46. Gandhi M, Medvedovic M, Stringer JR & Nikiforov YE. Interphase chromosome folding determines spatial proximity of genes participating in carcinogenic RET/PTC rearrangements. Oncogene 2006 25 2360-2366.
47. Roccato K, Bressan P, Sabatella G, Rumio C, Vizzotto L, Pierotti MA & Greco A. Proximity of TPR and NTRK1 rearranging loci in human thyrocytes. Cancer Research 2005 65 2572-2576.
48. Melillo RM, Castellone MD, Guarino V, De Falco V, Cirafici AM, Salvatore G, Caiazzo F, Basolo F, Giannini R, Kruhoffer M, Orntoft T, Fusco A & Santoro M. The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. Journal of Clinical Investigation 2005 115 1068-1081.
49. Wang J, Knauf JA, Basu S, Puxeddu E, Kuroda H, Santoro M, Fusco A & Fagin JA. Conditional expression of RET/PTC induces a weak oncogenic drive in thyroid PCCL3 cells and inhibits thyrotropin action at multiple levels. Molecular Endocrinology 2003 17 1425-1436.
50. Knauf JA, Kuroda H, Basu S & Fagin JA. RET/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase. Oncogene 2003 22 4406-4412.
51. Castellone MD, Cirafici AM, De Vita G, De Falco V, Malorni L, Tallini G, Fagin JA, Fusco A, Melillo RM & Santoro M. Ras-mediated apoptosis of PC CL 3 rat thyroid cells induced by RET/PTC oncogenes. Oncogene 2003 22 246-255.
52. Fischer AH, Bond JA, Taysavang P, Battles OE & Wynford-Thomas D. Papillary thyroid carcinoma oncogene (RFT/PTC) alters the nuclear envelope and chromatin structure. American Journal of Pathology 1998 153 1443-1450.
53. Santoro M, Chiappetta G, Cerrato A, Salvatore D, Zhang L, Manzo G, Picone A, Portella G, Santelli G, Vecchio G & Fusco A. Development of thyroid papillary carcinomas secondary to tissue-specific expression of the RET/PTC1 oncogene in transgenic mice. Oncogene 1996 12 1821-1826.
54. Jhiang SM, Sagartz JE, Tong Q, Parker-Thornburg J, Capen CC, Cho JY, Xing S & Ledent C. Targeted expression of the ret/PTC1 oncogene induces papillary thyroid carcinomas. Endocrinology 1996 137 375-378.
55. Powell DJ Jr, Russell J, Nibu K, Li G, Rhee E, Liao M. Goldstein M, Keane WM, Santoro M, Fusco A & Rothstein JL. The RET/PTC3 oncogene: metastatic solid-type papillary carcinomas in murine thyroids. Cancer Research 1998 58 5523-5528.
56. Basolo F, Giannini R, Monaco C, Melillo RM, Carlomagno F, Pancrazi M, Salvatore G, Chiappetta G, Pacini F, Elisei R, Miccoli P, Pinchera A, Fusco A & Santoro M. Potent mitogenicity of the RFT/PTC3 oncogene correlates with its prevalence in tall-cell variant of papillary thyroid carcinoma. American Journal of Pathology 2002 160 247-254.
57. Celetti A, Cerrato A, Merolla F, Vitagliano D, Vecchio G & Grieco M. H4(D10S170), a gene frequently rearranged with RET in papillary thyroid carcinomas: functional characterization. Oncogene 2004 23 109-121.
58. Monaco C, Visconti R, Barone MV, Pierantoni GM, Berlingieri MT, De Lorenzo C, Mineo A, Vecchio G, Fusco A & Santoro M. The RFG oligomerization domain mediates kinase activation and re-localization of the RET/PTC3 oncoprotein to the plasma membrane. Oncogene 2001 20 599-608.
59. Bunone G, Uggeri M, Mondellini P, Pierotti MA & Bongarzone I, RET receptor expression in thyroid follicular epithelial cell-derived tumors. Cancer Research 2000 60 2845-2849.
60. Melillo RM, Cirafici AM, De Falco V, Bellantoni M, Chiappetta G, Fusco A, Carlomagno F, Picascia A, Tramontano D, Tallini G & Santoro M. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma. American Journal of Pathology 2004 165 511-521.
61. Tong Q, Xing S & Jhiang SM. Leucine zipper-mediated dimerization is essential for the PTC1 oncogenic activity. Journal of Biological Chemistry 1993 272 9043-9047.
62. Iervolino A, Iuliano R, Trapasso F, Viglietto G, Melillo RM, Carlomagno F, Santoro M & Fusco A. The receptor-type protein tyrosine phosphatase J antagonizes the biochemical and biological effects of RET-derived oncoproteins. Cancer Research 2006 66 6280-6287.
63. Durick K, Gill GN & Taylor SS. Shc and Enigma are both required for mitogenic signaling by Ret/ptc2. Molecular and Cellular Biology 1998 18 2298-2308.
64. Melillo RM, Santoro M, Ong SH, Billaud M, Fusco A, Hadari YR, Schlessinger J & Lax I. Docking protein FRS2 links the protein tyrosine kinase RET and its oncogenic forms with the mitogen-activated protein kinase signaling cascade. Molecular and Cellular Biology 2001 21 4177-4187.
65. Bossis I & Stratakis CA. Minireview: PRKAR1A: normal and abnormal functions. Endocrinology 2004 145 5452-5458.
66. Griffin KJ, Kirschner LS, Matyakhina L, Stergiopoulos S, Robinson-White A, Lenherr S, Weinberg FD, Claflin E, Meoli E, Cho-Chung YS & Stratakis CA. Down-regulation of regulatory subunit type 1A of protein kinase A leads to endocrine and other tumors. Cancer Research 2004 64 8811-8815.
67. Dupont S, Zacchigna L, Cordenonsi M, Soligo S, Adorno M, Rugge M & Piccolo S. Germ-layer specification and control of cell growth by Ectodermin, a Smad4 ubiquitin ligase. Cell 2005 121 87-99.
68. Yeh S & Chang C. Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells. PNAS 1996 93 5517-5521.
69. Heinlein CA, Ting HJ, Yeh S & Chang C. Identification of ARA70 as a ligand-enhanced coactivator for the peroxisome proliferator-activated receptor gamma. Journal of Biological Chemistry 1999 274 16147-16152.
70. Kulkarni S, Heath C, Parker S, Chase A, Iqbal S, Pocock CF, Kaeda J, Cwynarski K, Goldman JM & Cross NC. Fusion of H4/D10S170 to the platelet-derived growth factor receptor beta in BCR-ABL-negative myeloproliferative disorders with a t(5;10)(q33;q21). Cancer Research 2000 60 3592-3598.
71. Zhong S, Delva L, Rachez C, Cenciarelli C, Gandini D, Zhang H, Kalantry S, Freedman LP & Pandolli PP. A RA-dependent, tumour-growth suppressive transcription complex is the target of the PML-RARalpha and T18 oncoproteins. Nature Genetics 1999 23 287-295.
72. Bousquet M, Quelen C, De Mas V, Duchayne E, Roquefeuil B, Delsol G, Laurent G, Dastugue N & Brousset P. The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene. Oncogene 2005 24 7248-7252.
73. Xing M. BRAF mutation in thyroid cancer. Endocrine-Related Cancer 2005 12 245-262.
74. Fagin JA. Challenging dogma in thyroid cancer molecular genetics-role of RET/PTC and BRAF in tumor initiation. Journal of Clinical Endocrinology and Metabolism 2004 89 4264-4266.
75. Kodama Y, Asai N, Kawai K, Jijiwa M, Murakumo Y, Ichihara M & Takahashi M. The RET proto-oncogene: a molecular therapeutic target in thyroid cancer. Cancer Science 2005 96 143-148.
76. Mitsutake N, Miyagishi M, Mitsutake S, Akeno N, Mesa C, Jr, Knauf JA, Zhang L, Taira K & Fagin JA. BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis. Endocrinology 2006 147 1014-1019.
77. Buckwalter TL, Venkateswaran A, Lavender M, La Perle KM, Cho JY, Robinson ML & Jhiang SM. The roles of phosphotyrosines- 294, -404, and -451 in RET/PTC1-induced thyroid tumor formation. Oncogene 2002 21 8166-8172.
78. Mesa C Jr, Mirza M, Mitsutake N, Sartor M, Medvedovic M, Tomlinson C, Knauf JA, Weber GF & Fagin JA. Conditional activation of RET/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling. Cancer Research 2006 66 6521-6529.
79. Sebolt-Leopold JS & Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nature Reviews Cancer 2004 4 937-947.
80. Knauf JA, Ouyang B, Knudsen ES, Fukasawa K, Babcock G & Fagin JA. Oncogenic RAS induces accelerated transition through G2/M and promotes defects in the G2 DNA damage and mitotic spindle checkpoints. Journal of Biological Chemistry 2006 281 3800-3809.
81. Knauf JA, Ma X, Smith EP, Zhang L, Mitsutake N, Liao XH, Refetoff S, Nikiforov YE & Fagin JA. Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Research 2005 65 4238-4245.
82. Giordano TJ, Kuick R, Thomas DG, Misek DE, Vinco M, Sanders D, Zhu Z, Ciampi R, Roh M, Shedden K, Gauger P, Doherty G, Thompson NW, Hanash S, Koenig RJ & Nikiforov YE. Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene 2005 24 6646-6656.
83. Frattini M, Ferrario C, Bressan P, Balestra D, De Cecco L, Mondellini P, Bongarzone I, Collini P, Gariboldi M, Pilotti S, Pierotti MA & Greco A. Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene 2004 23 7436-7440.
84. Russell JP, Shinohara S, Melillo RM, Castallone MD, Santoro M & Rothstein JL. Tyrosine kinase oncoprotein, RET/PTC3, induces the secretion of myeloid growth and chemotactic factors. Oncogene 2003 22 4569-4577.
85. Puxeddu E. Knauf JA, Sartor MA, Mitsutake N, Smith EP, Medvedovic M, Tomlinson CR, Moretti S & Fagin JA. RET/PTC-induced gene expression in thyroid PCCL3 cells reveals early activation of genes involved in regulation of the immune response. Endocrine-Related Cancer 2005 12 319-334.
86. Borrello MG, Alberti L, Fischer A, Degl'innocenti D, Ferrario C, Gariboldi M, Marchesi F, Allavena P, Greco A, Collini P, Pilotti S, Cassinelli G, Bressan P, Fugazzola L, Mantovani A & Pierotti MA. Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene. PNAS 2005 102 14825-14830.
87. Castellone MD, Celetti A, Guarino V, Cirafici AM, Basolo F, Giannini R, Medico E, Kruhoffer M, Orntoft TF, Curcio F, Fusco A, Melillo RM & Santoro M. Autocrine stimulation by osteopontin plays a pivotal role in the expression of the mitogenic and invasive phenotype of RET/ PTC-transformed thyroid cells. Oncogene 2004 23 2188-2196.
88. Castellone MD, Guarino V, De Falco V, Carlomagno F, Basolo F, Faviana P, Kruhoffer M, Orntoft T, Russell JP, Rothstein JL, Fusco A, Santoro M & Melillo RM. Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomas. Oncogene 2004 23 5958-5967.
89. Puxeddu E, Mitsutake N, Knauf JA, Moretti S, Kim HW, Seta KA, Brockman D, Myatt L, Millhorn DE & Fagin JA. Microsomal prostaglandin E2 synthase-1 is induced by conditional expression of RET/PTC in thyroid PCCL3 cells through the activation of the MEK-ERK pathway. Journal of Biological Chemistry 2003 278 52131-52138.
90. Russell JP, Engiles JB & Rothstein JL. Proinflammatory mediators and genetic background in oncogene mediated tumor progression. Journal of Immunology 2004 172 4059-4067.
91. Ouyang B, Knauf JA, Smith EP, Zhang L, Ramsey T, Yusuff N, Batt D & Fagin JA. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo. Clinical Cancer Research 2006 12 1785-1793.